DOP2015000170A - Compuestos químicos - Google Patents
Compuestos químicosInfo
- Publication number
- DOP2015000170A DOP2015000170A DO2015000170A DO2015000170A DOP2015000170A DO P2015000170 A DOP2015000170 A DO P2015000170A DO 2015000170 A DO2015000170 A DO 2015000170A DO 2015000170 A DO2015000170 A DO 2015000170A DO P2015000170 A DOP2015000170 A DO P2015000170A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- chemical compounds
- compounds
- processes
- formula
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
La invención se relaciona con compuestos de Fórmula (I) (I) o sales farmacéuticamente aceptables de los mismos, en donde R1 y R2 tienen cualquiera de los significados definidos anteriormente en la presente en la descripción; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento de trastornos proliferativos celulares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305078 | 2013-01-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2015000170A true DOP2015000170A (es) | 2015-08-16 |
Family
ID=47623992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2015000170A DOP2015000170A (es) | 2013-01-23 | 2015-07-16 | Compuestos químicos |
Country Status (27)
Country | Link |
---|---|
US (2) | US9156831B2 (es) |
EP (1) | EP2948447B1 (es) |
JP (1) | JP6307096B2 (es) |
KR (1) | KR102202516B1 (es) |
CN (1) | CN104936953B (es) |
AP (1) | AP2015008604A0 (es) |
AR (1) | AR094553A1 (es) |
AU (1) | AU2014208964B2 (es) |
BR (1) | BR112015017331B1 (es) |
CA (1) | CA2897279C (es) |
CL (1) | CL2015002027A1 (es) |
CR (1) | CR20150367A (es) |
DO (1) | DOP2015000170A (es) |
ES (1) | ES2608395T3 (es) |
HK (1) | HK1214592A1 (es) |
IL (1) | IL239890A0 (es) |
MA (1) | MA38287B1 (es) |
MX (1) | MX361136B (es) |
NI (1) | NI201500096A (es) |
PE (1) | PE20151979A1 (es) |
PH (1) | PH12015501584A1 (es) |
RU (1) | RU2644769C2 (es) |
SG (1) | SG11201505631PA (es) |
TN (1) | TN2015000313A1 (es) |
TW (1) | TWI606047B (es) |
UY (1) | UY35275A (es) |
WO (1) | WO2014114928A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
TW201726140A (zh) * | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
CN107137405A (zh) * | 2017-04-14 | 2017-09-08 | 黄德莲 | 一种治疗肾炎的药物组合物 |
CN110317190A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑-羧酸酯类衍生物在医药领域的应用 |
JP2022509019A (ja) | 2018-11-05 | 2022-01-20 | シンジェンタ パーティシペーションズ アーゲー | 殺有害生物的に活性なアゾール-アミド化合物 |
CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
JP2022523434A (ja) | 2019-03-08 | 2022-04-22 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性なアゾール-アミド化合物 |
WO2020188014A1 (en) | 2019-03-20 | 2020-09-24 | Syngenta Crop Protection Ag | Pesticidally active azole amide compounds |
JP2022525809A (ja) | 2019-03-22 | 2022-05-19 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺虫剤としてのn-[1-(5-ブロモ-2-ピリミジン-2-イル-1,2,4-トリアゾール-3-イル)エチル]-2-シクロプロピル-6-(トリフルオロメチル)ピリジン-4-カルボキサミド誘導体及び関連化合物 |
AU2021260109A1 (en) | 2020-04-24 | 2022-12-15 | Astrazeneca Ab | Pharmaceutical formulations |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7112373A (es) | 1970-09-25 | 1972-03-28 | ||
US4256887A (en) | 1978-04-06 | 1981-03-17 | Merck & Co., Inc. | 1,2,4-Triazoles and a method for their preparation |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
JP3028168B2 (ja) | 1993-03-29 | 2000-04-04 | 住化ファインケム株式会社 | ベンゼンスルホンアミド誘導体の製造方法 |
US5656416A (en) | 1994-12-22 | 1997-08-12 | Eastman Kodak Company | Photographic processing composition and method using organic catalyst for peroxide bleaching agent |
CN1151147C (zh) | 1995-02-02 | 2004-05-26 | 史密丝克莱恩比彻姆有限公司 | 作为5-ht受体拮抗剂的吲哚衍生物 |
GB9517559D0 (en) | 1995-08-26 | 1995-10-25 | Smithkline Beecham Plc | Novel compounds |
ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
WO1998004560A1 (en) | 1996-07-25 | 1998-02-05 | Merck Sharp & Dohme Limited | SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE |
GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
CN1443184A (zh) | 2000-07-19 | 2003-09-17 | 霍夫曼-拉罗奇有限公司 | 嘧啶衍生物 |
ES2333586T3 (es) | 2001-11-21 | 2010-02-24 | PHARMACIA & UPJOHN COMPANY LLC | Derivados de aril 1,4-pirazina sustituidos. |
US7012077B2 (en) | 2001-12-20 | 2006-03-14 | Hoffmann-La Roche Inc. | Substituted cyclohexane derivatives |
WO2003062224A1 (en) | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
CA2484209C (en) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
GB0306097D0 (en) | 2003-03-15 | 2003-04-23 | Elam T Ltd | Electroluminescent complexes |
JP2006520794A (ja) | 2003-03-21 | 2006-09-14 | スミスクライン ビーチャム コーポレーション | 化合物 |
DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
CA2545427C (en) | 2004-01-12 | 2012-08-21 | Cytopia Research Pty Ltd | Selective kinase inhibitors |
WO2005121126A1 (en) | 2004-04-13 | 2005-12-22 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
JP2006028056A (ja) | 2004-07-14 | 2006-02-02 | Agro Kanesho Co Ltd | ピリミジン誘導体及びこれを含む有害生物防除剤 |
ATE432926T1 (de) | 2004-07-26 | 2009-06-15 | Lilly Co Eli | Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung |
MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
CN101083994A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途 |
WO2006034315A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
EP1827436A4 (en) | 2004-12-15 | 2011-08-10 | Merck Sharp & Dohme | ACTIVITY INHIBITORS AKT |
WO2006084030A2 (en) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
NZ563423A (en) | 2005-06-10 | 2010-05-28 | Merck Sharp & Dohme | Inhibitors of AKT activity |
WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
CN101479255B (zh) | 2006-03-22 | 2013-05-01 | 沃泰克斯药物股份有限公司 | 用于治疗增殖性病症的c-MET蛋白激酶抑制剂 |
TW200808800A (en) | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
ATE456565T1 (de) | 2006-06-22 | 2010-02-15 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren |
EP3305297A1 (en) | 2006-06-30 | 2018-04-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases through inhibition of hsp90 |
EP2057124A2 (en) | 2006-07-21 | 2009-05-13 | Irm, Llc | Compounds and compositions as itpkb inhibitors |
JP5227321B2 (ja) | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体 |
EP2151437A4 (en) | 2007-03-07 | 2012-05-02 | Nissan Chemical Ind Ltd | ISOXAZOLINE SUBSTITUTED BENZAMIDE COMPOUND AND PEST CONTROL AGENT |
MX2010001746A (es) | 2007-08-14 | 2010-03-10 | Bayer Schering Pharma Ag | Pirimidinas biciclicas fusionadas. |
WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
CN101861321B (zh) | 2007-10-11 | 2013-02-06 | 阿斯利康(瑞典)有限公司 | 作为蛋白激酶b抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
KR20100089090A (ko) | 2007-10-25 | 2010-08-11 | 아스트라제네카 아베 | 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체 |
EP2230230A4 (en) | 2007-12-07 | 2011-03-16 | Nissan Chemical Ind Ltd | SUBSTITUTED DIHYDROAZOL COMPOUND AND PESTICIDES |
US20100298286A1 (en) | 2007-12-20 | 2010-11-25 | Novartis Ag | Organic Compounds |
JP2011507848A (ja) | 2007-12-21 | 2011-03-10 | ザ スクリプス リサーチ インスティチュート | Rhoキナーゼインヒビターとしてのベンゾピランおよびアナログ |
EP2310391A1 (en) | 2008-06-27 | 2011-04-20 | S*BIO Pte Ltd | Pyrazine substituted purines |
EP2342190A1 (en) | 2008-09-02 | 2011-07-13 | Novartis AG | Bicyclic kinase inhibitors |
JP2010083883A (ja) | 2008-09-08 | 2010-04-15 | Nissan Chem Ind Ltd | イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤 |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
JP2010063863A (ja) | 2008-09-11 | 2010-03-25 | Mugen:Kk | ヘッドのフェース部背面に音響振動の異なるパイプまたは平板を複数設けた打点位置表示型ゴルフ練習用クラブとその製法 |
CN101676271B (zh) | 2008-09-17 | 2011-12-14 | 山东轩竹医药科技有限公司 | 含有不饱和杂环胺的四环素衍生物 |
JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
WO2010054763A1 (de) * | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte aryl-verbindungen als hif-inhibitoren |
SI3354650T1 (sl) * | 2008-12-19 | 2022-06-30 | Vertex Pharmaceuticals Incorporated | Spojine, uporabne kot zaviralci ATR kinaze |
RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
US8957064B2 (en) | 2009-02-13 | 2015-02-17 | Bayer Intellectual Property Gmbh | Fused pyrimidines |
CN102361872B (zh) * | 2009-02-13 | 2014-12-03 | 拜耳知识产权有限责任公司 | 作为akt抑制剂的稠合嘧啶 |
EP2408780A2 (en) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3.3.1¨nonanes |
GB0909441D0 (en) | 2009-06-02 | 2009-07-15 | Univ Sheffield | Novel indole derivatives |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
US8354403B2 (en) | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
MX2012004020A (es) | 2009-10-20 | 2012-05-08 | Cellzome Ltd | Analogos de heterociclilo pirazolopirimidina como inhibidores de jak. |
US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
WO2011089400A1 (en) | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
ES2667049T3 (es) | 2010-02-05 | 2018-05-09 | Merck Patent Gmbh | Derivados de heteroaril-[1,8]naftiridina |
JP2011178673A (ja) | 2010-02-26 | 2011-09-15 | Nissan Chem Ind Ltd | 非農園芸害虫の防除方法 |
SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
RU2012153675A (ru) | 2010-05-12 | 2014-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные в качестве ингибиторов atr киназы |
CN102311396B (zh) | 2010-07-05 | 2015-01-07 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
CA2812091C (en) | 2010-09-14 | 2020-03-24 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
KR20130087020A (ko) * | 2010-09-16 | 2013-08-05 | 허치슨 메디파르마 리미티드 | 축합 헤테로아릴 및 그 용도 |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN102718745A (zh) * | 2011-03-30 | 2012-10-10 | 中国科学院上海药物研究所 | 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
CA2837312A1 (en) | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof |
WO2013049591A2 (en) | 2011-09-29 | 2013-04-04 | Verseon Corporation | Dual inhibitor compounds and methods of use thereof |
PL2833973T3 (pl) | 2012-04-05 | 2018-02-28 | Vertex Pharmaceuticals Incorporated | Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone |
-
2014
- 2014-01-22 MX MX2015009465A patent/MX361136B/es active IP Right Grant
- 2014-01-22 BR BR112015017331-4A patent/BR112015017331B1/pt active IP Right Grant
- 2014-01-22 SG SG11201505631PA patent/SG11201505631PA/en unknown
- 2014-01-22 KR KR1020157021103A patent/KR102202516B1/ko active IP Right Grant
- 2014-01-22 ES ES14701828.7T patent/ES2608395T3/es active Active
- 2014-01-22 PE PE2015001341A patent/PE20151979A1/es not_active Application Discontinuation
- 2014-01-22 EP EP14701828.7A patent/EP2948447B1/en active Active
- 2014-01-22 WO PCT/GB2014/050163 patent/WO2014114928A1/en active Application Filing
- 2014-01-22 CA CA2897279A patent/CA2897279C/en active Active
- 2014-01-22 US US14/160,650 patent/US9156831B2/en active Active
- 2014-01-22 RU RU2015132370A patent/RU2644769C2/ru active
- 2014-01-22 MA MA38287A patent/MA38287B1/fr unknown
- 2014-01-22 AU AU2014208964A patent/AU2014208964B2/en active Active
- 2014-01-22 JP JP2015554244A patent/JP6307096B2/ja active Active
- 2014-01-22 AP AP2015008604A patent/AP2015008604A0/xx unknown
- 2014-01-22 AR ARP140100196A patent/AR094553A1/es unknown
- 2014-01-22 CN CN201480005179.8A patent/CN104936953B/zh active Active
- 2014-01-23 UY UY0001035275A patent/UY35275A/es not_active Application Discontinuation
- 2014-01-23 TW TW103102536A patent/TWI606047B/zh active
-
2015
- 2015-07-09 IL IL239890A patent/IL239890A0/en unknown
- 2015-07-10 CR CR20150367A patent/CR20150367A/es unknown
- 2015-07-16 DO DO2015000170A patent/DOP2015000170A/es unknown
- 2015-07-16 PH PH12015501584A patent/PH12015501584A1/en unknown
- 2015-07-21 CL CL2015002027A patent/CL2015002027A1/es unknown
- 2015-07-22 NI NI201500096A patent/NI201500096A/es unknown
- 2015-07-22 TN TN2015000313A patent/TN2015000313A1/en unknown
- 2015-08-31 US US14/840,209 patent/US9657008B2/en active Active
-
2016
- 2016-03-04 HK HK16102484.1A patent/HK1214592A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201500167A (es) | Compuestos químicos | |
DOP2015000170A (es) | Compuestos químicos | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
UY36285A (es) | Compuestos que inhiben la proteína mcl-1 | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
GT201500094A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
NI201500140A (es) | Compuestos y composiciones terapéuticos | |
DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
ECSP14013215A (es) | Compuestos novedosos | |
ECSP16074478A (es) | Compuestos novedosos | |
DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
MX2016006509A (es) | Compuestos triciclicos de piperidina. | |
GT201500189A (es) | Inhibidores de autotaxina | |
CU20150048A7 (es) | Compuestos heteroaromáticos como ligandos d1 de dopamina | |
CR20150584A (es) | Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b | |
NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa |